- South Korea
- /
- Pharma
- /
- KOSE:A000100
Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We note that Yuhan Corporation (KRX:000100) does have debt on its balance sheet. But is this debt a concern to shareholders?
When Is Debt Dangerous?
Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take control of the business. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. The first step when considering a company's debt levels is to consider its cash and debt together.
What Is Yuhan's Debt?
As you can see below, at the end of March 2025, Yuhan had ₩364.1b of debt, up from ₩247.6b a year ago. Click the image for more detail. However, because it has a cash reserve of ₩357.9b, its net debt is less, at about ₩6.18b.
How Strong Is Yuhan's Balance Sheet?
According to the last reported balance sheet, Yuhan had liabilities of ₩693.4b due within 12 months, and liabilities of ₩175.1b due beyond 12 months. Offsetting this, it had ₩357.9b in cash and ₩620.3b in receivables that were due within 12 months. So it actually has ₩109.8b more liquid assets than total liabilities.
This state of affairs indicates that Yuhan's balance sheet looks quite solid, as its total liabilities are just about equal to its liquid assets. So it's very unlikely that the ₩7.75t company is short on cash, but still worth keeping an eye on the balance sheet. Carrying virtually no net debt, Yuhan has a very light debt load indeed.
See our latest analysis for Yuhan
We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio).
Yuhan's debt of just 0.049 times EBITDA is really very modest. And EBIT easily covered the interest expense 8.4 times over, lending force to that view. On top of that, Yuhan grew its EBIT by 74% over the last twelve months, and that growth will make it easier to handle its debt. The balance sheet is clearly the area to focus on when you are analysing debt. But it is future earnings, more than anything, that will determine Yuhan's ability to maintain a healthy balance sheet going forward. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.
But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So the logical step is to look at the proportion of that EBIT that is matched by actual free cash flow. During the last three years, Yuhan burned a lot of cash. While that may be a result of expenditure for growth, it does make the debt far more risky.
Our View
The good news is that Yuhan's demonstrated ability to grow its EBIT delights us like a fluffy puppy does a toddler. But we must concede we find its conversion of EBIT to free cash flow has the opposite effect. Looking at all the aforementioned factors together, it strikes us that Yuhan can handle its debt fairly comfortably. Of course, while this leverage can enhance returns on equity, it does bring more risk, so it's worth keeping an eye on this one. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. We've identified 2 warning signs with Yuhan , and understanding them should be part of your investment process.
If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSE:A000100
Yuhan
Operates as a pharmaceutical company in South Korea and internationally.
Excellent balance sheet with proven track record.
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.
Recently Updated Narratives

OceanaGold: Potential Upside with High Costs and Mid-Tier Status

Second order memory play likely to double in a year

Still A Binary Phase III Bet on Evenamide
Popular Narratives
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality
NVIDIA will see a profit margin surge of 55% in the next 5 years
